The global Peptide Therapeutics Market is predicted to reach USD 48.04 billion by 2025 owing to the rise in demand for efficient & speedy treatment of cancer and other lifestyle-related disorders. Peptides are the naturally occurring biological molecules that are used in drugs to improve the patient’s medical condition. They are highly safe and effective due to which they are widely accepted by physicians and patients for treating several ailments.
In medical practice, they are ideal for diabetes, infectious diseases, several types of cancers, cardiovascular, and other medical conditions. Peptides are highly modifiable and versatile in comparison to other drugs, which makes them highly profitable to sponsors. Due to their feature of versatility, they are used in multiple medical conditions which leads to higher penetration of the peptide therapeutics industry. Apart from therapeutics effects, the market is also gaining attraction due to comparatively easy marketing approval and familiarity.
Along with the growing prevalence of cardiovascular disorders and cancers, the increasing research & development activities and rich peptide therapeutics pipeline are predicted to support the growth of the market in near future. The patent expiration of various peptide drugs in the future is expected to create ample opportunities for the market contributing to its growth at a significant rate.
Peptide therapeutics have application in CNS (Central Nervous System) disorders and respiratory disorders due to features like safety, efficiency, and versatility. Advanced research & development facilities and new peptide developments by pharma companies are driving the demand for reasonably priced peptide therapeutics.
Nevertheless, the large-scale production of peptides with increasing complexities of peptides is a major challenge for the peptide therapeutics market. The development of multifunctional peptides and the rise in a number of collaboration for the progress of peptide conjugates are currently ruling the market.
The latest advances in peptide synthesis technology are projected to be the key driver for the growth of the peptide therapeutics industry. Among the different methods of peptide synthesis, enzymatic and chemical synthesis are important. This technology has integrated structure-activity relationships (SARs) and analog generation to increase bioavailability, increase safety & efficacy of drugs, impart protease resistance, reduce adverse effects, and develop formulations.
The other driving factor of the market is the shift towards unexploited markets. The market is witnessing several vendors focusing on developing economies due to the presence of large population groups and clinical trial subjects. Factors like the presence of lenient regulatory guidelines, skilled labor, limited market competition, and low manufacturing costs will encourage vendors to shift their manufacturing processes to developing economies.
The peptide therapeutics market is categorized based on application, technology, route of administration, molecule type, API peptide type, and geography. Based on application, the market is divided into Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, Renal, etc. In terms of route of administration, the market is segmented as Parenteral, Oral, etc.
Based on type, the peptide therapeutics industry is divided into Innovative and Generic. Based on technology, the market is classified into Liquid Phase, Solid Phase, and Hybrid Phase. Type of Molecule is classified into Vasopressin, Somatostatin, Calcitonin, Immunopeptide, Natriuretic, and others. Based on API Peptide Type, the market is divided into In-house and CMO (contract manufacturing organization).
Geographically, the peptide therapeutics market is segmented as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Latin America are predicted to hold a larger share of the market owing to the rising incidences of cancer and other lifestyle-related disorders.
The key peptide therapeutics industry players comprise AstraZeneca plc, Amgen Inc., Eli Lilly and Company, Sanofi, CordenPharma International GmbH, Teva Pharmaceutical Industries Ltd., Novartis AG, Ipsen S.A., Lonza Group Ltd., Merck & Co. Inc., F. Hoffmann-La Roche AG, Bachem Holding AG, PolyPeptide Group and Novo Nordisk A/S.
Peptide Therapeutics, Application Outlook (Revenue, USD Million; 2014 - 2025)
• Cardiovascular Disorder
Peptide Therapeutics, Type Outlook (Revenue, USD Million; 2014 - 2025)
Peptide Therapeutics, Type of Manufacturers Outlook (Revenue, USD Million; 2014 - 2025)
Peptide Therapeutics, Route of Administration Outlook (Revenue, USD Million; 2014 - 2025)
• Parenteral Route
• Oral Route
Peptide Therapeutics, Synthesis Technology Outlook (Revenue, USD Million; 2014 - 2025)
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology
Peptide Therapeutics, Regional Outlook (Revenue, USD Million; 2014 - 2025)
• North America
• the U.S.
• the UK
• the Asia Pacific
• Latin America
• South Africa
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...